OJEMDA DIN 02569817
Status: Marketed
Holder: IPSEN BIOPHARMACEUTICALS CANADA INC
Health Canada record
| Active ingredient(s) | TOVORAFENIB 100 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01EC04 TOVORAFENIB |
|---|
| Original market date | 07-Oct-2026 |
|---|
| Current status date | 07-Oct-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Ipsen Biopharmaceuticals Canada Inc — licence 102222, currently licensed, last inspection rating C (2024-05-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TOVORAFENIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02569876 | OJEMDA | IPSEN BIOPHARMACEUTICALS CANADA INC | Powder For Suspension | TOVORAFENIB 25 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37901 | 2026-07-13 | New Drug Submission (NDS) | |
Request a quote for OJEMDA
How to read a Canadian DIN record